ArticleDiscover oncology2025
A mendelian randomization study on the association between type 2 diabetes and the risk of bladder cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Type 2 diabetes mellitus and cancer: A systematic review and meta-analysis of Mendelian randomization studies.Frontiers in endocrinology · 2026Pooled it
- Nuclear hexokinase 2 couples hyperglycemia to MYC-driven glycolytic and stemness programs in bladder cancer.Cell death & disease · 2026Article
- Intersection of Precision Nutrition and Bladder Cancer: A Narrative State-of-the-Art Review of Potential Applications and Challenges.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe used Mendelian randomization (MR) analyses to examine the potential causal effects of type 2 diabetes and glycemic traits on bladder cancer risk.
methodsTwo-sample MR analyses were conducted using summary data from genome-wide association studies (GWAS). Exposures included type 2 diabetes, fasting glucose, glycosylated hemoglobin (HbA1c), fasting insulin, and proinsulin levels, with bladder cancer as the outcome. Four methods-inverse variance weighted, MR-Egger, weighted median, and weighted mode-were used to assess the causal effects. Sensitivity analyses were conducted to ensure that the results were robust.
resultsIn the inverse variance weighted model, a weak positive effect was detected between genetically predicted HbA1c and bladder cancer (OR = 1.003, 95% CI = 1.0001 to 1.0052, P = 0.043). Other MR methods produced results with the same trend, although not all were statistically significant. However, there was no evidence to support the effect of type 2 diabetes, fasting insulin, or proinsulin levels on bladder cancer. No significant heterogeneity or pleiotropy was detected.
conclusionMendelian randomization analysis indicated a mild promoting effect of increased HbA1c levels on bladder cancer risk. Further studies with larger sample sizes are needed to confirm this hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.